SG11202110745VA - Angptl2 antisense oligonucleotides and uses thereof - Google Patents
Angptl2 antisense oligonucleotides and uses thereofInfo
- Publication number
- SG11202110745VA SG11202110745VA SG11202110745VA SG11202110745VA SG11202110745VA SG 11202110745V A SG11202110745V A SG 11202110745VA SG 11202110745V A SG11202110745V A SG 11202110745VA SG 11202110745V A SG11202110745V A SG 11202110745VA SG 11202110745V A SG11202110745V A SG 11202110745VA
- Authority
- SG
- Singapore
- Prior art keywords
- angptl2
- antisense oligonucleotides
- antisense
- oligonucleotides
- angptl2 antisense
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962828864P | 2019-04-03 | 2019-04-03 | |
PCT/US2020/026379 WO2020206115A2 (en) | 2019-04-03 | 2020-04-02 | Angptl2 antisense oligonucleotides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110745VA true SG11202110745VA (en) | 2021-10-28 |
Family
ID=70465458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110745VA SG11202110745VA (en) | 2019-04-03 | 2020-04-02 | Angptl2 antisense oligonucleotides and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220213484A1 (en) |
EP (1) | EP3947680A2 (en) |
JP (1) | JP2022524218A (en) |
KR (1) | KR20210149107A (en) |
CN (1) | CN113906139A (en) |
AU (1) | AU2020252374A1 (en) |
BR (1) | BR112021019182A2 (en) |
CA (1) | CA3135794A1 (en) |
EA (1) | EA202192733A1 (en) |
IL (1) | IL286826A (en) |
MX (1) | MX2021012098A (en) |
SG (1) | SG11202110745VA (en) |
WO (1) | WO2020206115A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3131970B1 (en) | 2022-01-14 | 2024-02-23 | Univ D’Aix Marseille Amu | Device for simulation in abdominal surgery |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE69233046T2 (en) | 1991-10-24 | 2004-03-04 | Isis Pharmaceuticals, Inc., Carlsfeld | DERIVATIZED OLIGONUCLEOTIDS WITH IMPROVED CAPACITY |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
JP4236812B2 (en) | 1997-09-12 | 2009-03-11 | エクシコン エ/エス | Oligonucleotide analogues |
JPH11341989A (en) * | 1998-03-31 | 1999-12-14 | Sanyo Electric Co Ltd | Dna fragment amplification, dna fragment amplifier, microorganism group measurement, microorganism group analysis and pollutant measurement |
ES2234563T5 (en) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | New nucleoside and oligonucleotide analogs |
CA2372085C (en) | 1999-05-04 | 2009-10-27 | Exiqon A/S | L-ribo-lna analogues |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
EP2752488B1 (en) | 2002-11-18 | 2020-02-12 | Roche Innovation Center Copenhagen A/S | Antisense design |
EP1606406B2 (en) | 2003-03-21 | 2013-11-27 | Santaris Pharma A/S | SHORT INTERFERING RNA (siRNA) ANALOGUES |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
WO2007085485A2 (en) | 2006-01-27 | 2007-08-02 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
DK2314594T3 (en) | 2006-01-27 | 2014-10-27 | Isis Pharmaceuticals Inc | 6-modified bicyclic nucleic acid analogues |
DK2002004T3 (en) | 2006-03-23 | 2015-11-30 | Roche Innovation Ct Copenhagen As | LITTLE INTERNAL SEGMENTED INTERFERENCE RNA |
CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
EP2356129B1 (en) | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
CA2754749C (en) * | 2009-03-04 | 2019-04-30 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1 |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
EP2490699A1 (en) | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
WO2013033230A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
CN117126846A (en) | 2012-11-15 | 2023-11-28 | 罗氏创新中心哥本哈根有限公司 | Oligonucleotide conjugates |
WO2014167529A1 (en) * | 2013-04-10 | 2014-10-16 | Institut De Cardiologie De Montreal | Methods and compositions for preventing and treating atherosclerosis |
EP3633039A1 (en) | 2013-05-01 | 2020-04-08 | Ionis Pharmaceuticals, Inc. | Compositions and methods |
CN112263682A (en) | 2013-06-27 | 2021-01-26 | 罗氏创新中心哥本哈根有限公司 | Antisense oligomers and conjugates targeting PCSK9 |
MA41586A (en) * | 2015-02-04 | 2017-12-13 | Hoffmann La Roche | ANTISENSE OLIGOMERS OF TAU PROTEIN AND THEIR USES |
MX2019005816A (en) | 2016-11-23 | 2019-10-07 | Alnylam Pharmaceuticals Inc | Modified rna agents with reduced off-target effect. |
-
2020
- 2020-04-02 KR KR1020217035359A patent/KR20210149107A/en unknown
- 2020-04-02 EP EP20722089.8A patent/EP3947680A2/en active Pending
- 2020-04-02 SG SG11202110745VA patent/SG11202110745VA/en unknown
- 2020-04-02 MX MX2021012098A patent/MX2021012098A/en unknown
- 2020-04-02 CA CA3135794A patent/CA3135794A1/en active Pending
- 2020-04-02 BR BR112021019182A patent/BR112021019182A2/en unknown
- 2020-04-02 EA EA202192733A patent/EA202192733A1/en unknown
- 2020-04-02 US US17/594,154 patent/US20220213484A1/en active Pending
- 2020-04-02 CN CN202080039696.2A patent/CN113906139A/en active Pending
- 2020-04-02 WO PCT/US2020/026379 patent/WO2020206115A2/en unknown
- 2020-04-02 JP JP2021559064A patent/JP2022524218A/en active Pending
- 2020-04-02 AU AU2020252374A patent/AU2020252374A1/en active Pending
-
2021
- 2021-09-29 IL IL286826A patent/IL286826A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3135794A1 (en) | 2020-10-08 |
US20220213484A1 (en) | 2022-07-07 |
EA202192733A1 (en) | 2022-03-14 |
KR20210149107A (en) | 2021-12-08 |
JP2022524218A (en) | 2022-04-28 |
MX2021012098A (en) | 2021-11-03 |
WO2020206115A2 (en) | 2020-10-08 |
AU2020252374A1 (en) | 2021-11-11 |
CN113906139A (en) | 2022-01-07 |
IL286826A (en) | 2021-10-31 |
BR112021019182A2 (en) | 2022-05-31 |
EP3947680A2 (en) | 2022-02-09 |
WO2020206115A3 (en) | 2020-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276549A (en) | Camk2d antisense oligonucleotides and uses thereof | |
IL288418A (en) | 4'-phosphate analogs and oligonucleotides comprising the same | |
IL284882A (en) | Oligonucleotide compositions and methods thereof | |
SG11202105626TA (en) | Oligonucleotide compositions and methods thereof | |
GB2569462B (en) | The self-repairing anticorrosive coatings, preparation method and application thereof | |
IL275950A (en) | Alpha-synuclein antisense oligonucleotides and uses thereof | |
EP3914259A4 (en) | Rna-editing oligonucleotides and uses thereof | |
EP3914261A4 (en) | Rna-editing oligonucleotides and uses thereof | |
EP3914260A4 (en) | Rna-editing oligonucleotides and uses thereof | |
EP3601603A4 (en) | Oligonucleotide probes and uses thereof | |
EP4076448A4 (en) | Fluoroalkyl-oxadiazoles and uses thereof | |
IL280724A (en) | Chemically modified oligonucleotides targeting snps | |
IL275903A (en) | Antisense oligonucleotides targeting alpha-synuclein and uses thereof | |
EP3770256A4 (en) | Antisense oligonucleotide having reduced toxicity | |
IL275902A (en) | Antisense oligonucleotides targeting alpha-synuclein and uses thereof | |
ZA202203618B (en) | Mmup monomer variant and application thereof | |
EP3724206A4 (en) | Conjugated antisense compounds and their use | |
ZA202203568B (en) | Mnep monomer variant and application thereof | |
IL310303A (en) | Unc13a antisense oligonucleotides | |
EP3966328A4 (en) | Anti-c9orf72 oligonucleotides and related methods | |
EP3532617A4 (en) | Antisense oligonucleotides | |
IL286826A (en) | Angptl2 antisense oligonucleotides and uses thereof | |
EP4041248A4 (en) | Modified oligonucleotides | |
EP3999523A4 (en) | Melanophilin antisense oligonucleotides | |
EP4039804A4 (en) | Buckwheat-derived c-glycosyltransferase gene and utilization thereof |